




**Blueberries**  
Medical Corp.

# Annual Shareholder Meeting: Blueberries Medical Corp 22'-23' milestones and future perspectives

OCTOBER 2023



# Agenda



Blueberries  
Medical Corp.

**2 - 8** Commercial and Operative Milestones

---

**9 - 12** Financials

---

**12 - 13** Management Team and Board of Directors

---

Q&A


---



**Blueberries**  
Medical Corp.

# Commercial and Operative Milestones

OCTOBER 2023  
PRIVATE AND CONFIDENTIAL



# First THC BBM's Commercial Operation

**In March/2023 BBM achieved its first THC and Australia Market sale.**



Australia is one of the most developed and active Cannabis markets.



THC inclusion into BBM portfolio



Due to regulatory barriers THC is less sensitive to commoditization



# First Pharmaceutical Cannabidiol Sale

**In October/2023 BBM achieved its first Cannabidiol sale for Pharmaceutical purposes.**



The pharmaceutical sector is less susceptible to changing Cannabis regulatory landscape.



Low flexibility to supplier changes.



Largest individual order along BBM history

# BBM advancing to global presence



# Sales at B2B2C Channel

## In September/2023 BBM received authorization for compounded formulations export to Brazil



CAD 200 MM market size for 2023 with expected CAGR 2023-2028 of 16%



There are over 160,000 patients located in Brazil.



BBM's exportation of a finished product plays a vital role in generating high-added value and increased margins.

# Sales at B2B2C Channel

## In September/2023 BBM received authorization for compounded formulations export to Brazil



CAD 200 MM market size for 2023 with expected CAGR 2023-2028 of 16%



There are over 160,000 patients located in Brazil.




BBM's exportation of a finished product plays a vital role in generating high-added value and increased margins.



# Retaining and Growing Access to International Markets



EU-GMP A to Z Finished Products Facility: High CAPEX and limited access to the Brazilian market.



More pressure on the operation can lead to a decrease in specialization.



# BBM has signed a joint venture agreement with Laboratorios Nutripharma.



+20 years building up  
LatAm Market



Products are available in 10  
different countries.



5 different pharmaceutical  
dosage forms including  
soft-gel



FDA registered and INVIMA  
GMP certified



# BBM has entered into a JV agreement with Nutripharma

+10 countries are now available

+7 new final product and co-processed categories

Access to largest LatAm market



- \* BBM will launch finished products in Brazil, and is expecting additional 30% revenue on 2025
- \* Cost optimization via mutual capabilities sharing.
- \* New revenue streams for BBM associated with ingredients for NP and other natural ingredients players

**CO-PROCESSING & FINAL PRODUCTS**

**EXTRACTION & DOWNSTREAM**

**ENGINEERING & INFRAESTRUCTURE**

**PHARMACEUTICAL AND REGULATORY EXPERIENCE**






**Blueberries**  
Medical Corp.


# Financial Projections & Sales Evolution

OCTOBER 2023






# Sales evolution and projection (thousands of CAD)







# Total Net Cash (in thousands of CAD)




■ Operating net cash ■ Investing net cash ▲ Total net cash

# Financial Performance Forecast






# Comparative Stock Performance for Colombia Operations based Cannabis Company (2023)



- BBRRF
- CLVR
- KHRN



# Management Team



**Gustavo  
Gutiérrez**  
Country Manager



**Facundo  
Garretón**  
Chairman



**Guillermo  
Rodríguez**  
Chief Financial Officer



**Thomas  
Rodríguez**  
Financial Director

# Board of Directors

*Years of Experience*

**Facundo Garretón**  
Chairman & Interim CEO



**20+**

**Patricio Villalba**  
Founding Director



**20+**

**Catherine Lathwell**  
Director



**10+**

**Joaquín Barbera**  
Director



**20+**

**José Forero (New)**  
Director



**15+**



# Blueberries Medical Corp purpose



***Unlocking the therapeutical potential of plants for life-threatening health conditions***



**Blueberries**  
Medical Corp.

**Gustavo Gutiérrez**  
Country Manager

☎ +57 317 667 48 12

✉ [ggutierrez@blueberriesmed.com](mailto:ggutierrez@blueberriesmed.com)

**Guillermo Rodríguez**  
Chief Financial Officer

☎ +54 9 11 6015 2227

✉ [grodriguez@blueberriesmed.com](mailto:grodriguez@blueberriesmed.com)

**Thomas Rodríguez**  
Financial Director

☎ +57 311 617 42 46

✉ [trodriguez@blueberriesmed.com](mailto:trodriguez@blueberriesmed.com)